» Articles » PMID: 33085022

The Histological Representativeness of Glioblastoma Tissue Samples

Overview
Specialty Neurosurgery
Date 2020 Oct 21
PMID 33085022
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Glioblastomas (GBMs) are known for having a vastly heterogenous histopathology. Several studies have shown that GBMs can be histologically undergraded due to sampling errors of small tissue samples. We sought to explore to what extent histological features in GBMs are dependent on the amount of viable tissue on routine slides from both biopsied and resected tumors.

Methods: In 106 newly diagnosed GBM patients, we investigated associations between the presence or degree of 24 histopathological and two immunohistochemical features and the tissue amount on hematoxylin-eosin (HE) slides. The amount of viable tissue was semiquantitatively categorized as "sparse," "medium," or "substantial" for each case. Tissue amount was also assessed for associations with MRI volumetrics and the type of surgical procedure.

Results: About half (46%) of the assessed histological and immunohistochemical features were significantly associated with tissue amount. The significant features were less present or of a lesser degree when the tissue amount was smaller. Among the significant features were most of the features relevant for diffuse astrocytic tumor grading, i.e., small necroses, palisades, microvascular proliferation, atypia, mitotic count, and Ki-67/MIB-1 proliferative index (PI).

Conclusion: A substantial proportion of the assessed histological features were at risk of being underrepresented when the amount of viable tissue on HE slides was limited. Most of the grading features were dependent on tissue amount, which underlines the importance of considering sampling errors in diffuse astrocytic tumor grading. Our findings also highlight the importance of adequate tissue collection to increase the quality of diagnostics and histological research.

Citing Articles

Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction.

Erickson A, Jackson L, Camphausen K, Krauze A Biomedicines. 2025; 12(12.

PMID: 39767713 PMC: 11673638. DOI: 10.3390/biomedicines12122806.


Mutations in the , , , and Genes and Their Relationship with Resistance to Temozolomide in Patients with High-Grade Gliomas.

Ortiz Gomez L, Contreras Martinez H, Galvis Pareja D, Velez Gomez S, Salazar Florez J, Monroy F Biomedicines. 2025; 12(12.

PMID: 39767683 PMC: 11673431. DOI: 10.3390/biomedicines12122777.


Innovative Approaches to Brain Cancer: The Use of Magnetic Resonance-guided Focused Ultrasound in Glioma Therapy.

Cwiklinska A, Przewodowska D, Koziorowski D, Szlufik S Cancers (Basel). 2025; 16(24.

PMID: 39766134 PMC: 11674718. DOI: 10.3390/cancers16244235.


Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.

Jacome M, Wu Q, Pina Y, Etame A Cancers (Basel). 2024; 16(21).

PMID: 39518074 PMC: 11544870. DOI: 10.3390/cancers16213635.


Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables.

Bomsztyk K, Mar D, Denisenko O, Powell S, Vishnoi M, Yin Z Lab Invest. 2024; 104(12):102160.

PMID: 39426568 PMC: 11709230. DOI: 10.1016/j.labinv.2024.102160.


References
1.
Brat D, Van Meir E . Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest. 2004; 84(4):397-405. DOI: 10.1038/labinvest.3700070. View

2.
Brat D, Aldape K, Colman H, Holland E, Louis D, Jenkins R . cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018; 136(5):805-810. PMC: 6204285. DOI: 10.1007/s00401-018-1913-0. View

3.
Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama S . The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-77. PMC: 3910500. DOI: 10.1016/j.cell.2013.09.034. View

4.
Bruner J, Inouye L, Fuller G, Langford L . Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer. 1997; 79(4):796-803. DOI: 10.1002/(sici)1097-0142(19970215)79:4<796::aid-cncr17>3.0.co;2-v. View

5.
Capper D, Jones D, Sill M, Hovestadt V, Schrimpf D, Sturm D . DNA methylation-based classification of central nervous system tumours. Nature. 2018; 555(7697):469-474. PMC: 6093218. DOI: 10.1038/nature26000. View